FF-21101

FF-21101 is a human–mouse chimeric monoclonal antibody that targets P-cadherin (cadherin-3/CDH3), a cell adhesion molecule overexpressed in various solid tumors including colorectal, ovarian, pancreatic-biliary, and lung cancers[1][7]. The drug is developed as a radioimmunoconjugate by linking the antibody to radioactive isotopes such as yttrium-90 (90Y) or indium-111 (111In) via a DOTA chelator[1][5]. As a radiopharmaceutical, it delivers cytotoxic ionizing radiation directly to tumor cells expressing P-cadherin. This targeted approach aims to maximize tumor cell death while minimizing damage to healthy tissue. In addition to direct DNA damage from beta radiation emitted by 90Y, there is evidence that the therapy may also modulate the insulin-like growth factor 1 receptor (IGF‑1R) pathway involved in cancer cell survival and resistance[6]. Clinical trials have shown preliminary efficacy and manageable toxicity in heavily pre-treated patients with advanced solid tumors[2][3].

Other names

CDH3-radioisotope-labelled antibodyCDH-3-radioisotope-labelled antibodyCDH 3-radioisotope-labelled antibodychimeric monoclonal antibody targeting human cadherin-3